Status:
COMPLETED
Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer
Lead Sponsor:
Fukushima Medical University
Collaborating Sponsors:
Human Genome Center, Institute of Medical Science, University of Tokyo
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, immune response and clinical response of different doses of HLA-A\*2402 restricted epitope peptides URLC10, TTK, VEGFR1 and VEGFR2 em...
Detailed Description
URLC10 and TTK have been identified as cancer specific molecules especially in non small cell lung cancer using genome-wide expression profile analysis by cDNA microarray technique. We have determined...
Eligibility Criteria
Inclusion
- Disease characteristics
- Advanced or recurrent non small cell lung cancer
- Second line or later therapeutic status
- Patient characteristics
- ECOG performance status 0-2
- Life expectancy \> 3 months
- HLA-A\*2402
- Laboratory values as follows 1500/mm3\<WBC\<15000/mm3 Platelet count\>75000/mm3 Bilirubin \< 3.0mg/dl Asparate transaminase \< 99IU/L Alanine transaminase \< 126IU/L Creatinine \< 2.2mg/dl
- Able and willing to give valid written informed consent
Exclusion
- Active and uncontrolled cardiac disease (includes patients with myocardial infarction within 6 months before entry)
- Pregnancy (woman of child bearing potential)
- Active and uncontrolled infectious disease
- Adrenal cortical steroid hormone dependent status
- Decision of unsuitableness by principal investigator
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00633724
Start Date
May 1 2007
End Date
June 1 2012
Last Update
August 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fukushima Medical University Hospital
Fukushima, Fuskushima, Japan, 960-1295